US Edition
News from daily-tribune.com
We’ve assigned a rating of Unknown factuality to Daily-tribune.com. You can read more about how we’ve determined Daily-tribune.com’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Daily-tribune.com News
Shanghai, China · ShanghaiSHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo…See the Story
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
56% Center coverage: 9 sources
GLP-1 · WilmingtonNew multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition.See the Story
MENU - ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users
62% Center coverage: 8 sources
Maryland · MarylandLEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve non-small cell lung…See the Story
Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
62% Center coverage: 8 sources
